Nab-paclitaxel

About

Therapy type: Chemotherapy

Therapy strategy: Taxane-based chemotherapy

Mappings

NCI Thesaurus: Nab-paclitaxel (ncit:C2688)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
Sensitivity (+) Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+) Wild type ALK Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel